Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

New York Times Examines Trend Of Posting Childbirth Videos On YouTube
The New York Times on Thursday examined how thousands of women have posted videos on YouTube showing themselves giving birth. According to the Times, the women believe the videos help "demystify" childbirth by candidly presenting the process in a manner that pregnant women and their partners otherwise might not see. Along with YouTube, Web sites like Internet chat rooms and pregnancy blogs are helping to shift dynamics between pregnant women and their care providers, the Times reports. Eileen Ehudin Beard, an adviser for the American College of Nurse-Midwives, said, "The more information you have, the more s you have, the more informed you are, the better questions you ask." However, she added that the videos could have negative effects, particularly if they make women more fearful of childbirth. The childbirth videos are relatively controversial because of their graphic nature, which has challenged some of YouTube"s rules and raised issues of propriety. Victoria Grand, the head of policy for YouTube, said that nudity generally is banned from YouTube but that the site "make[s] exceptions for videos that are educational, documentary or scientific." Most childbirth videos on YouTube are age restricted to ages 18 and older. A majority of them show home births because most U.S. hospitals prohibit patients from recording births due to liability concerns, the Times reports. Although childbirth education classes have shown edited videos of births since the 1970s, the Internet and YouTube could change the way such classes are taught, according to Jeanette Schwartz, president of the International Childbirth Education Association. She noted that most videos currently used in childbirth classes are heavily edited and out of date, adding that the YouTube videos "create a wonderful opportunity to show free, real life, candid videos in a classroom setting." Eugene Declercq, a professor at the Boston University School of Public Health, said, "A hundred and fifty years ago, women viewed birth on a pretty regular basis -- they saw their sisters of neighbors give birth." He said that changed with a trend toward hospital births beginning in the late 19th century. "But now, with YouTube, we"ve come back around and women have this opportunity to view births again," Declercq said (Wollan, New York Times, 6/11).
generic viagra online
Federal Appeals Court Rejects Lawsuit Against Abbott Over HIV/AIDS Drug Price Hike
Federal Appeals Court Rejects Lawsuit Against Abbott Over HIV/AIDS Drug Price Hike
News of the day
AAP President-Elect Testifies Before Senate Committee, Applauds Attention To Children's Benefits
The American Academy of Pediatrics (AAP), a non-profit professional organization of
Sexual Health

Multiple Sclerosis Patients Benefit From Diabetes Drug

A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology. In a small, double-blinded clinical trial, patients with relapsing remitting multiple sclerosis were assigned to take pioglitazone (a drug commercially known as Actos used to treat type-2 diabetes) or a placebo. Patients continued their normal course of therapy during the trial. Standard neurological tests were done initially, as were MRI scans to provide baseline values for lesions typically seen in MS patients. The patients were evaluated every two months, and blood samples were taken. Repeat MRI scans were done after five months and again after one year. Patients taking pioglitazone showed significantly less loss of gray matter over the course of the one-year trial than patients taking placebo. Of the 21 patients who finished the study, patients taking pioglitazone had no adverse reactions and, further, found taking pioglitazone, which is administered in an oral tablet, easy. "This is very encouraging," said Douglas Feinstein, research professor of anesthesiology at UIC. "Gray matter in the brain is the part that is rich in neurons. These preliminary results suggest that the drug has important effects on neuronal survival." Feinstein"s lab has been interested in the class of drugs called thiazolidinediones, or TZDs. Several TZDs have been approved for use in the treatment of type-2 diabetes because of the drugs" effect on the body"s response to insulin. The researchers focused on pioglitazone because of its known anti-inflammatory effects, Feinstein said. They used primary cultures of brain cells to show that pioglitazone reduced the production of toxic chemicals called cytokines and reactive oxygen species. These molecules are believed to be important in the development of symptoms in MS. Feinstein"s lab proceeded to test pioglitazone in an animal model of MS. They and others showed that pioglitazone and other TZDs "can significantly reduce the clinical signs in mice with an MS-type disease," said Feinstein. "More importantly, when mice who are already ill are treated with pioglitazone, the clinical signs of the disease go away," he said. "We were able to induce almost complete remissions in a number of mice." "We are now working to determine the mechanisms to explain the protective effect on neurons that we see in our studies," said Feinstein. "We hope to expand into a larger trial to confirm these preliminary results." Claudia C. Kaiser, who was a post-doctoral student at UIC, is first author on the paper. Other authors are Dinesh Shukla and Demetrios Shias of UIC; Glen Stebbins, Dusan Stefoski and George Katsamakis of Rush University Medical Center; and Douglas Jeffrey of Wake Forest University School of Medicine. Takeda Pharmaceuticals funded the study and provided the drug but had no other involvement in the study. Jeanne Galatzer-Levy University of Illinois at Chicago


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009